About us
We improve prostate cancer survival and patient care, by providing clinical tools for individualized treatment based on patient tumor biology.
Phenotype Diagnostics was founded in 2021 to translate discoveries in world-leading academic research into clinical usefulness for the benefit of patients. Led by a team of tumor biology experts and clinician scientists, Phenotype Diagnostics develops methods for precise diagnostics by considering biological characteristics, i.e. the tumor phenotype of individual patients. The company is currently developing two clinical products, one for computational pathology and the other for liquid biopsy analysis.
Global health issue
Prostate cancer is the 2nd most common cancer in men worldwide, and a leading cause to cancer mortality. About 1,4 million men are diagnosed with prostate cancer every year (about 11000 in Sweden), and the incidence is increasing due to an ageing population. Today, about 25% of all men diagnosed with prostate cancer die from their disease due to inadequate treatment of metastases (spread to other organs, mainly to the bone).
Expensive theraphy with different modes of action
Metastatic prostate cancer is treated with androgen-deprivation therapy (castration) followed by complementary therapies with different modes of actions. The therapies are expensive and come with troublesome side-effects, and as patients show large diversites in response, therapy should be selected based on each patient´s probability to respond.
Unmet need
Today there are no confident clinical tools for selecting the best treatment option for individual patients with metastatic prostate cancer.
Our solution
Phenotype Diagnostics develops methods for precise diagnostics by considering the biological tumor characteristics in individual patients. In this way, optimal therapy can be given to each patitient resulting in better care, longer survival and reduced costs, without the risk of overtreatment.
Management
Advisors
Andreas Josefsson, PhD, MD Urology, Umeå University Hospital
Camilla Thellenberg Karlsson, PhD, MD Oncology, Umeå University Hospital
Jonas Nilsson, PhD, expert liquid biopsies, Umeå University
Karin Welén, PhD, expert liquid biopsies, Gothenburg University
Peter Jacobsson, Business coach, Umeå Biotech Incubator
Andreas Lindberg, Business coach, Umeå Biotech Incubator